Eliot Charles, MiroBio executive chairman

Look­ing to bol­ster im­mune check­point R&D, Gilead buys Miro­Bio as it takes next-gen check­point ther­a­py to the clin­ic

While Gilead dropped dis­ap­point­ing da­ta on its Ar­cus-part­nered CD37 in­hibitor Wednes­day af­ter­noon, the bio­phar­ma is mak­ing moves to cush­ion its im­mune check­point pipeline. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.